{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-26-001697","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.018890+00:00","generated_at":"2026-05-15T08:24:32.585934+00:00","sec_items":["3.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InMed receives Nasdaq notice of bid price deficiency; 180 days to cure","bullets":["Received Nasdaq notice on March 27, 2026; closing bid price below $1.00 for 30 consecutive days (Feb 11–Mar 26).","Must achieve $1.00 or more for 10 consecutive business days within 180 calendar days to regain compliance.","If not cured, may qualify for additional 180-day period, subject to other listing standards and possible reverse split.","No immediate effect on listing; shares continue trading on Nasdaq under symbol INM.","Company monitoring share price and exploring options, including reverse stock split if needed."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-26-001697","json":"https://secwatch.observer/filing/0001062993-26-001697.json","markdown":"https://secwatch.observer/filing/0001062993-26-001697.md","text":"https://secwatch.observer/filing/0001062993-26-001697.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326001697/0001062993-26-001697-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326001697/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:24:32.585934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6680686ee12f6bcf82efda56053d979aa4e7e9b2","claim":"InMed Pharmaceuticals Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"March 27, 2026, InMed Pharmaceuticals Inc. (the \"Company\") received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\"Nasdaq\") notifying it that the closing bid price of the Company's common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) during the February 11, 2026 to March 26, 2026 period. In accordance with applicable Nasdaq procedures, the Company has a period of 180 calendar days following the receipt of t","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326001697/0001062993-26-001697-index.htm","confidence":0.98,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}